Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05919147 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia

Study acronym: TRACE-1
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Identification, Study Status, Sponsor/Collaboratorsv6
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  3. Start date: Jul 18, 2023 to Jan 3, 2024v4
  4. Eligibility criteria expanded, about 3 words
    • Study title shortened, about 1 word
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2023 to Jul 18, 2023
    • Site details revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is evaluate the effect of pioglitazone compared with placebo on skeletal muscle insulin sensitivity in subjects with cancer and cachexia.
Trial Details
NCT Number NCT05919147
Lead Sponsor Pennington Biomedical Research Center
Conditions
(from sponsor)		 Lung Cancer
Related terms Lung Neoplasms
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov